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For most patients with type I diabetes, insulin therapy and glucose monitoring are sufficient
to maintain glycemic control. However, hypoglycemia is a potentially lethal side effect of in-
sulin treatment in patients who are glycemically labile or have hypoglycemia-associated au-
tonomic failure [1]. For those patients, an alternative therapy is beta cell replacement via
pancreas or islet transplantation. Pancreas transplants using cadaveric donor organs re-
duce insulin dependence but carry risks involved in major surgery and chronic immuno-
suppression. Islet transplantation, in which islets are isolated from donor pancreases and
intravenously infused, require no surgery and can utilize islets isolated from pancreases un-
suitable for whole organ transplantation. However, islet transplantation also requires im-
munosuppression, and standard steroid regimens may be toxic to beta cells [2]. The 2000
Edmonton Trial demonstrated the first long-term successful islet transplantation by using a
glucocorticoid-free immunosuppressive regimen (sirolimus and tacrolimus). The Clinical Islet
Transplantation (CIT†) Consortium seeks to improve upon the Edmonton Protocol by using
anti-thymocyte globulin (ATG) and TNFʱ antagonist (etanercept). The trials currently in
progress, in addition to research efforts to find new sources of islet cells, reflect enormous
potential for islet transplantation in treatment of type I diabetes. 
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The neeD for alTernaTIve
TherapIes In Type I DIabeTes
Type I diabetes mellitus is a chronic au-
toimmune disease resulting from selective
destruction of insulin-producing beta cells
in the islets of Langerhans [3]. The absolute
deficiency of insulin results in a wide spec-
trum of metabolic dysfunction, particularly
impaired glucose homeostasis. The discov-
ery of insulin in 1922 was a monumental
achievement, transforming type I diabetes
mellitus from a death sentence to a manage-
able, chronic condition. The Diabetes Con-
trol  and  Complications  Trial  (DCCT)
confirmed that tight glucose control prevents
or even reverses long-term complications of
type 1 diabetes [4]. However, insulin ther-
apy itself can be life-threatening, as an over-
dose can result in severe hypoglycemia. In
fact, tight glucose control is associated with
more frequent episodes of hypoglycemia,
especially in patients during acute illnesses
[5]. Many patients experience wide excur-
sions in plasma glucose levels that lead to
the  secondary  complications  of  diabetes,
since most existing insulin formulations can-
not mimic the natural regulatory ability of
the insulin-producing beta cells of the en-
docrine pancreas. Of note, more recent in-
novations in insulin delivery and therapy,
such as insulin degludec (an ultra-long-act-
ing basal insulin analog that can last up to
40 hours) has been shown to potentially
mimic normal body glycemic control better
than existing 24 hour-based regimens using
long-acting insulin analog glargine [6]. 
Many insulin-dependent type I diabetes
patients have some degree of hypoglycemia
unawareness,  the  inability  to  sense  low
blood glucose, thus the benefits of stringent
glycemic control may be outweighed by the
risk of a potentially fatal insulin overdose
[7]. Up to 10 percent of mortality in patients
with type I diabetes is the result of hypo-
glycemia unawareness [8], which potentially
causes loss of consciousness or inability to
awaken  from  sleep  (“dead-in-bed”  syn-
drome) [9]. That autonomic neuropathy is
both  caused  by  hypoglycemia  (“hypo-
glycemia-associated  autonomic  failure”)
and makes hypoglycemia more likely, form-
ing a vicious cycle [7]. Despite advances in
insulin  therapy,  the  frequency  of  hypo-
glycemia unawareness has not declined in
the past two decades [10], thus alternative
therapies are required. In the following sec-
tions, we will discuss efforts to restore phys-
iologic glucose homeostasis by beta cell
replacement, which can be accomplished ei-
ther  via  whole  pancreas  or  isolated  islet
transplantation. 
pancreas TransplanTaTIon
The first successful pancreas transplan-
tations were simultaneous kidney-pancreas
(SPK) transplants performed in 1966 in two
patients with end-stage diabetic nephropa-
thy [11]. One of the two recipients from this
original  study  achieved  near-normal
glycemia for approximately 2 months post-
transplant [12]. Type I diabetes patients that
have undergone a successful kidney trans-
plant are candidates for pancreas-after-kid-
ney  (PAK)  transplantation.  Furthermore,
type I diabetes patients with normal renal
function  and  affected  with  severe  hypo-
glycemic unawareness and glucose lability
have been treated with pancreas transplant
alone (PTA). The success rates of SPK and
PAK transplants have continued to improve,
while peri- and post-operative morbidity and
mortality have steadily declined. SPK and
PAK transplants improve quality of life and
reduce  hyperglycemia-related  complica-
tions, including decreasing or reversing dia-
betic neuropathy [12].
However, these benefits come with the
risks of chronic immunosuppression, surgi-
cal complications, and graft rejection [13].
Standard medical therapy with insulin and
close glucose monitoring are safe and suc-
cessful in most patients with type I diabetes,
thus the American Diabetes Association be-
lieves that isolated pancreatic transplants
carry unjustified risks [14,15]. Due to the
significant improvements in the length and
quality of life in patients with type I diabetes
who adhere to intensive medical therapy
alone, one study claims that PTA and PAK
transplantation are associated with an in-
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transplant, by 57 percent and 42 percent re-
spectively, compared to patients with type I
diabetes who remained on the transplant
waiting list [13]. However, this study was
challenged by another report that found a
significant benefit for patients undergoing
pancreas transplants [16,17].
IsleT TransplanTaTIon
The advantage of islet transplantation is
avoidance of the major surgery needed for
whole pancreas transplantation. However,
like pancreas transplants, isolated islets are
susceptible to immunologic rejection despite
maintenance immunosuppression. The mod-
ern era of islet transplantation began in 1972
with reports from two laboratories demon-
strating successful reversal of diabetes in ro-
dents  by  isolated  islet  transplantation
[18,19]. Since then, a number of critical
milestones have been achieved, providing a
platform for translation of this innovative
therapy for treatment of type I diabetes pa-
tients. These include: 1) selection of the por-
tal vein and liver as a site for inoculation of
isolated islets [20]; 2) an automated method
for isolation of human pancreatic islets [21];
and 3) improvements in collagenase enzyme
blend for isolation and purification of islets.
According  to  the  Collaborative  Islet
Transplant Registry (CITR) report, the peri-
procedural complications of islet transplan-
tation  have  an  estimated  20-fold  lower
morbidity risk than pancreatic transplants
[22]. Another advantage of islet transplanta-
tion is that healthy islets can be isolated
from pancreases that may not be used for
whole pancreas transplantation, which is ex-
tremely valuable given the shortage of donor
organs [23]. 
IsleT TransplanTaTIon: 
eDMonTon proTocol 
The landmark trial of islet transplanta-
tion in 2000 by the Edmonton group [24]
demonstrated successful reversal of diabetes
in seven consecutive type I diabetes patients.
The trial utilized induction immunosuppres-
sion with daclizumab (a monoclonal anti-
body to the IL-2 receptor) and maintenance
with a glucocorticoid-free immunosuppres-
sive regimen consisting of the calcineurin in-
hibitor tacrolimus and the mTOR inhibitor
sirolimus. The islet transplant recipients had
suffered  from  recurrent  severe  hypo-
glycemia. After transplantation, insulin treat-
ment was stopped; if serum glucose reached
>200mg/dL, another transplantation was per-
formed. All seven patients required second
islet transplantations, while one required a
third. The investigators did not observe any
acute rejection and recorded only mild side
effects due to the immunosuppression, such
as sirolimus-induced superficial buccal ul-
cerations. At 1 year of follow-up, all seven
patients  were  insulin-independent,  their
serum glucose levels showed less fluctua-
tion, and none suffered episodes of severe
hypoglycemia. However, longer follow-up
revealed progressive loss of beta cell func-
tion and recurrence of diabetes. In a trial of
65  patients  conducted  by  the  Edmonton
group in 2004, only 10 percent of the patients
remained insulin-independent at 5 years, al-
though partial graft function persisted in 80
percent of the patients [25].
In 2006, the reproducibility of the Ed-
monton protocol was tested in 36 patients at
nine international academic centers [26].
The trial achieved more sobering results and
saw large differences in islet graft function
among the various centers. After 1 year, only
16 of the 36 patients were still insulin-inde-
pendent; 10 patients maintained partial graft
function, and 10 had complete graft loss.
After 3 years, only one patient remained in-
sulin-independent. But even though nearly
all patients resumed insulin therapy, patients
with  partial  islet  function  nonetheless
demonstrated  improvement  in  glycemic
control and protection from hypoglycemia
compared to their pre-transplant states.
Some investigators saw the progressive
graft loss and lack of reproducibility as fatal
flaws of the Edmonton protocol [27]. Inves-
tigators from Bergamo, Italy, criticized the
method and mission of islet transplantation
and announced abandonment of their own
clinical islet cell transplantation program
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were used for a single islet cell transplant,
they believed islet transplants to be “a waste
of valuable donated organs,” especially with
a persistent shortage of human donors. Ad-
ditionally,  they  raised  the  concern  that
sirolimus and tacrolimus may inhibit beta
cell regeneration and cause nephrotoxicity
in the long term. Also, the potential devel-
opment of alloantibodies after failed islet
transplantation may increase the recipients’
risk of later rejecting whole pancreas and
kidney transplants, which may be required
following islet cell transplant failure [29].
In response to the criticisms, the Ed-
monton group dismissed the Italian aban-
donment of islet transplantation as “entirely
personal,”  and  that  “clinicians  and  re-
searchers involved in the majority of pro-
grams do not share the pessimistic view
expressed by the Italian group” [30]. They
indicated that many patients did achieve
complete insulin independence, and despite
graft loss after a few years, recipients were
nonetheless  protected  from  severe  hypo-
glycemia. Falling short of complete insulin
independence, they wrote, should not call
for abandonment of islet transplantation;
even partial islet graft survival may suffice if
the most important goal is to prevent hypo-
glycemia unawareness and tragic “death-in-
bed” events.
IsleT TransplanTaTIon: 
buIlDIng on eDMonTon
In 2004, the Clinical Islet Transplanta-
tion (CIT) Consortium was established in
eight academic centers under the guidance
of the National Institutes of Health (NIH)
and  U.S.  Food  and  Drug Administration
(FDA) to conduct islet transplantation in two
cohorts: islet-alone transplantation in type I
diabetes subjects with severe hypoglycemia
unawareness (CIT-07) and islet-after-kidney
transplantation in subjects with prior suc-
cessful kidney transplantation (CIT- 06). A
number of important modifications were im-
plemented:  1)  uniform  and  standardized
manufacturing of isolated islets utilizing im-
proved collagenase enzyme blend; 2) induc-
tion immunotherapy with polyclonal anti-
thymocyte globulin ATG and TNFʱ antago-
nist  [31];  3)  a  steroid-free  maintenance
immunosuppression regimen composed of
low-dose calcineurin inhibitor (tacrolimus)
and mTOR inhibitor (rapamycin); and 4) in
vitro culture of islets prior to transplantation.  
ATG is a polyclonal antibody with the
capacity to delete and inhibit anti-islet allo-
and auto-immune T-cells and contains sev-
eral species of antibodies targeting B-cells,
adhesion molecules, and integrins needed
for diapedesis of lymphoid cells [32]. TNFʱ
antagonist interferes with early post-trans-
plant immune response, blocks direct cyto-
toxic effect of TNFʱ on murine islet beta
cells [33], and limits cytokine release syn-
drome associated with ATG administration.
In vitro culture of islets for 48 to 72
hours yields a “cleaner” islet suspension
with less immunogenic and thrombogenic
collagen and debris, a higher yield of viable
islet cells, and permits quality control meta-
bolic testing and sterility prior to islet trans-
plantation [34].  
The consortium investigators seek to
demonstrate effectiveness of islet transplan-
tation in type I diabetes patients with severe
hypoglycemic  unawareness  (at  least  one
episode of severe hypoglycemia in the 12
months  before  enrollment).  The  primary
endpoint of the trial is the proportion of sub-
jects rendered insulin-independent and free
of severe hypoglycemic events a year fol-
lowing the first islet cell transplant, as well
as having a hemoglobin A1c (HbA1c) of
less than 7 percent. Since HbA1c is a marker
of red blood glycation as a result of expo-
sure to plasma glucose, achieving a near-
normal HbA1c is a good marker of glycemic
control  over  a  period  of  2  to  3  months,
which is the average lifespan of a red blood
cell [35]. Estimated completion dates for
analysis of the data are January 2013 for
CIT-06 and September 2012 for CIT-07.
oTher aDvances In IsleT
TransplanTaTIon
Despite the paramount advances made
in  islet  transplantation  in  the  last  few
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ample, islet cell harvest from whole pan-
creas  remains  a  limiting  step,  as  the
efficiency of harvest and cell viability post-
harvest is relatively poor. While many labo-
ratories are developing methods to improve
these processes, given the severe shortage of
donor pancreases, other investigators are ex-
ploring alternative sources of beta cells.
One possibility is to derive pancreatic
islet cells de novo from human embryonic
stem cells (hESCs). Recently, it has been
shown that the small molecule (-)-indolac-
tam V induces differentiation of  hESCs into
pancreatic progenitor cells in vitro [36]. The
more plentiful pancreatic ductal cells isolated
from human donor pancreases can be trans-
differentiated into the more scarce beta-cells
[37].  Similarly,  mouse  experiments  have
shown that bile duct epithelial cells [38], aci-
nar cells [39], and hepatic cells [40] can also
be trans-differentiated into beta-cells. The
differentiation of human fibroblast-derived
induced pluripotent stem cells (iPSCs) into
beta-cells provides another alternative that is
particularly  enticing  due  to  its  potential
avoidance of allogeneic rejection [41]. Addi-
tionally, since porcine insulin is closely ho-
mologous  to  human  insulin,  islet  cell
xenografts using porcine cells are also being
investigated [42]. While these methods of de
novo islet cell generation technologies hold
great promise, much optimization and pa-
tient-safety testing remains before they will
be feasible alternative sources of islet cells. 
Further investigations are focused on
creating  an  artificial  immune-privileged
micro-environment to prevent rejection of
transplanted islets. Current attempts are under
way to develop polymer encapsulations of
islet cells that are permeable to oxygen, glu-
cose, nutrients, and insulin, but not antibodies
or cytokines. However, a major technical hur-
dle is inadequate oxygen perfusion of cells
within the encapsulated islets, which leads to
ischemic necrosis in their centers [43]. Main-
taining graft survival and function remains
the primary difficulty for developing safe and
effective islet transplantation.
Advances in our understanding of im-
munobiology of organ rejection in general,
specifically the induction of donor-specific
tolerance, also provide a pathway for the
widespread utilization of islet transplanta-
tion for treatment of type I diabetes [44].
conclusIon
Islet cell transplantation is a promising
potential therapy for patients with type I di-
abetes with hypoglycemia unawareness or
glycemic  lability.  Unlike  pancreas  trans-
plantation, it does not require invasive sur-
gery, and it can utilize islets isolated from
suboptimal  deceased  donor  pancreases.
However, a number of technical challenges
remain in optimizing islet transplantation,
including the need to find less toxic im-
munosuppressive therapies to improve graft
survival. The Clinical Islet Transplantation
(CIT) Consortium has implemented logical
steps to advance the field, and trial results
are eagerly awaited. In addition to the chal-
lenges of immunosuppression, innovative
therapies to achieve glucose homeostasis
must work within or overcome the relative
scarcity  of  organ  donors.  The  ability  to
transdifferentiate non-islet cells into islet
cells may create a more plentiful supply of
islets for transplantation. In the future, islet
transplantation  could  transform  manage-
ment of type I diabetes not just for patients
with refractory difficulties in glycemic con-
trol, but for all type I diabetes patients.
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